Company Media

• Immuron (ASX:IMC) - IMM124E may offer new modality for inhibition of SARS-CoV-2

• ​Immuron (ASX:IMC) enters research agreement with Monash University (December 15, The Market Herald)

• Immuron (ASX:IMC) reveals positive anti-diarrhoea vaccine results (November 20, The Market Herald)

• ​Immuron takes steps towards FDA approval for stomach bug treatment (October 2020, The Market Herald)

• Immuron's stock pulls back but still still nearly doubles after stock offering (July 2020, Market Watch)

• Immuron’s commercially available products found to neutralise COVID-19 during in vitro research (July 2020, Apple News via Small Caps) 

• Could Immuron's travellers' diarrhea treatment be used to fight covid? (July 2020, The Market Herald)

• Immuron reveals anti-COVID potential and raised $28 million (July 2020, AU Manufacturing)

• Immuron and US Naval Medical Research Center prepare to develop novel oral therapeutic for E-Coli (June 2020, Small Caps)

Immuron reports diarrhea number 1 health issue for Americans on vacation (February 2020):

• Chicago Daily Herald

• The Buffalo News

• Tulsa World

• News on 6

• Yahoo Finance

• SKAL International

• SKAL International New York

• OTT Travel

• California Travel Association

• Travel Writers Network

• Sightseers' Delight

• The Forward Cabin

• Global Business Travel Association

Travel Influencer Sponsored Content, USA Campaign (February 2020):

• How to maintain tummy health on your next trip (The Blonde Abroad)

• What to do you when you get sick while traveling (Be My Travel Muse)

• Maintaining a Healthy Digestive System While Traveling (A Broken Back Pack)

• Packing list for South East Asia (A Broken Back Pack)

• Tips to avoid getting sick in South East Asia (A Broken Back Pack)

• 9 things to pack in your first aid kit (Go World Travel)

• Social media posts

• Immuron's stock pulls back but still nearly doubles after stock offering 

• Immuron's commercially available products found to neutralise COVID-19 during in vitro research

• Immuron's stock blasts off nearly 10-fold after partner NMRC seeks pre-IND meeting with FDA

• Immuron (ASX:IMC) develops research agreement

• Immuron and US Naval Medical Research prepare to develop novel oral therapeutic for E.coli

• Walter Reid Army Institute of Research 2019 Year in Review

• Immuron partnering with Walter Reid Army Institute of Research to test Travelan against Shigella, ETEC, Vibrio cholerae and Campylobacter jejuni isolates (2020, WRAIR's Investigator's Dispatch)

• Diarrhea a major health issue for Americans traveling abroad (February 2020, Ask Health News)

• Immuron's shares rise on the back of Travelan® results (June 2019, Finfeed)

• Travelan on The Not Old Better Show with Dr. Hailey Weerts - Research Scientist of Walter Reed Army Institute of Research WRAIR

• Immuron CEO interviewed on the RedChip Money Report, USA

• Immuron and US Department of Defense look to develop silver bullet for gastro infections (July 2018, Small Caps)  

• US Defense finishes latest research on Immuron’s Travelan (July 2018, Finfeed)

• Immuron Travelan passes projects (July 2018, News.com.au)

• No crap: Immuron is one step closer to an anti-gastro pill (July 2018, Stockhead)

• Big Pharma is watching as Immuron edges towards trial results (June 2018, Stockhead)

• Immuron reduces liver inflammation (Mar 2018, Nine Finance)

• Immuron positive clinical trial results fight fatty liver disease (Mar 2018, Small Caps)

• Shares in Australian pharma Immuron are going nuts (Mar 2018, Business Insider)

• Immuron's IMM-124E shows encouraging action in mid-stage NASH study (Mar 2018, Seeking Alpha)

• Immuron shares surge on demonstrating proof of concept for liver drug candidates (Mar 2018, Proactive Investors)

• Results in: IMC's lead drug reduces major factor in liver inflammation (Mar 2018, Finfeed)

• Blockbuster results from IMC's NASH liver therapy trials (Mar 2018, NextBiotech)

• How do you recruit patients unaware of their disease (Clinical Leader)

• Are these unsanitary things really that bad for you? (Oct 2017, Healthyway)

• Immuron's fatty liver disease candidate advancing - 4 insights (Sept 2017, Becker's GI and Endoscopy)

• In dash to NASH, Immuron targets the gut not the liver (Mar 2017, MedCity News)

• 2017 Bioshares Biotech Summit coverage - IMM-124E targets the gut and the microbiome (Bioshares)

• Biotech tackles hospital infection (The Australian, Mar 2017)

• Immuron to start search for partner or buyer of fatty liver therapeutics in Q1 2017 (Oct 2016, Proactive Investors - Merger Market)

• Protect yourself from mosquito bites while traveling this summer  (April 2016, Arizona Midday)

• Healthy and safe travel products  (April 2016, Good Day DC)

• 5 hot travel items (March 2016, What is Travelan and How Does it Work?)